Skip to main content
The George Institute for Global HealthThe George Institute for Global Health
Covid-19 Covid 19 Covid 19
Donate

Social links Global

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
The George Institute for Global Health
  • About us
    • Our Mission And Values
    • Our Strategy
    • Our History
    • How Our Research Is Different
    • Our People
    • Board Of Directors
    • Global Advisory Committee (ACRIS)
    • Our Affiliates And Collaborators
    • George Health
    • Annual Reports
    • Financial Statements
    • Environmental Sustainability Commitment
  • Our Work
    • Our Priorities
    • Better Treatments
    • Better Care
    • Healthier Societies
    • Ongoing Projects
    • Archived Projects
    • Publications
  • News & Events
    • Media Releases
    • News Stories
    • Media Coverage
    • Media Enquiries
    • Events
    • Past Events
    • Blogs / Profile Stories
    • E-Newsletters
    • Videos
    • Podcasts
  • Our Impact
    • Advocacy And Thought Leadership
    • Disruptive Social Entrepreneurship
    • Policy statements and recommendations
    • Case Studies And Examples
    • 20 Years Of Impact
    • Careers & studies
      • The George Experience
      • Current Job Opportunities
    • Contact Us
    • Get involved
      • Giving Opportunities
      • Building Back Better After COVID-19: The Research Agenda
      • Reclaiming Comprehensive Public Health: A Call to Action
      • Join Us Register
      • Clinical Trials

      Donate

    • Donate
    1. Home

    Search Results

    Displaying results 1 - 20 of 28

    Sort by:

    Published dateDatasourceRelevance Sort ascending
    • Professor Vlado Perkovic, of The George Institute, discusses the results of the CREDENCE kidney disease trial
      Professor Vlado Perkovic, of The George Institute, discusses the results of the CREDENCE kidney disease trial
      11/4/2019 -
      Video
      entity:node
      9,563,555,200,000
    • Professor Vlado Perkovic, of The George Institute, discusses the results of the CREDENCE kidney disease trial (with subtitles)
      11/4/2019 -
      Video
      entity:node
      9,498,543,500,000
    • Standalone grabs with Professor Vlado Perkovic, of The George Institute, discusses the results of the CREDENCE kidney disease trial
      Standalone grabs with Professor Vlado Perkovic, of The George Institute, discusses the results of the CREDENCE kidney disease trial
      11/4/2019 -
      Video
      entity:node
      9,466,368,000,000
    • Heralding a new era in kidney disease research and treatment: The CREDENCE trial
      The landmark clinical trial, CREDENCE, transformed the status quo in diabetic kidney disease research by identifying the first new treatment in almost 20 years. Building on The George Institute’s…
      09/3/2022 -
      Case Studies
      entity:node
      1,616,047,770,000
    • New breakthrough treatment for kidney disease offers hope for hundreds of millions of people with diabetes worldwide
      A new treatment for people with diabetes and kidney disease reduced kidney failure rates by a third, according to a landmark study. The results, published in the New England Journal of Medicine, also…
      14/4/2019 -
      Media release
      entity:node
      43,406,480
    • New study confirms protective effect of diabetes drugs against kidney failure
      Lead author Dr Brendon Neuen from The George Institute for Global Health commented:  “We found SGLT2 inhibitors clearly and powerfully reduce the risk of kidney failure.” “These findings…
      02/9/2019 -
      Media release
      entity:node
      41,104,104
    • Potential breakthrough treatment for chronic kidney disease and diabetes
      The CREDENCE trial, investigating a breakthrough treatment for chronic kidney disease and type 2 diabetes, has been ended early after benefit was demonstrated at an interim analysis. The study, being…
      17/7/2018 -
      Media release
      entity:node
      40,248,012
    • 20 years of game-changing kidney disease research
      For two decades, The George Institute has been at the forefront of global efforts to improve kidney disease treatment around the world, as Professor Vlado Perkovic explains. Vlado…
      12/11/2019 -
      Profile story
      entity:node
      175,530.03
    • Tackling diabetes is a critical and achievable goal
      The number of people living with diabetes is increasing worldwide at an alarming rate. According to the International Diabetes Federation (IDF), diabetes is one of the fastest growing health…
      13/11/2020 -
      News
      entity:node
      32,214.355
    • Breakthrough for kidney disease
      Worldwide, 160 million people with type 2 diabetes have or are at risk of developing chronic kidney disease. We identified the first new treatment for diabetic kidney disease in 20 years. The…
      25/2/2020 -
      Landing Page
      entity:node
      26,244.56
    • The George Institute’s three most read research stories of 2019!
      2019 has certainly been significant for The George Institute for Global Health - not only did we celebrate our 20th year but we also delivered ground-breaking research that will have a positive…
      20/12/2019 -
      News
      entity:node
      25,864.115
    • The George Institute's five most-read research stories in 2018
      Take a look at our five most-read research stories in 2018: 1. Innovative triple pill significantly lowers blood pressure A new low dose three in one pill to treat hypertension could transform…
      17/12/2018 -
      News
      entity:node
      25,742.266
    • Investment in diabetes treatment returns almost five times more in benefits to society
      1.7 million Australians have diabetes and around two-thirds also have cardiovascular disease, chronic kidney disease or both. Each year in Australia hospital admissions for cardiovascular disease and…
      17/3/2021 -
      News
      entity:node
      25,561.629
    • Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
      Publication
      entity:bibcite_reference
      0
    • Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY
      Publication
      entity:bibcite_reference
      0
    • Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
      Publication
      entity:bibcite_reference
      0
    • The effect of canagliflozin on amputation risk in the CANVAS Program and the CREDENCE trial.
      Publication
      entity:bibcite_reference
      0
    • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL
      03/2020 -
      Publication
      entity:bibcite_reference
      0
    • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
      03/2020 -
      Publication
      entity:bibcite_reference
      0
    • THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL
      03/2020 -
      Publication
      entity:bibcite_reference
      0

    Pagination

    • 1
    • 2
    • › Next page
    • » Last page

    Search

    Search

    Filter by type of content

    Publications
    People
    Research
    Media
    Events
    Impact report and case studies
    • About us
    • Our Work
    • News & Events
    • Our Impact
    • Careers & studies
    • Get involved
    • Thought leadership
    • Contact us
    • Donate

    The George Institute for Global Health

    Level 5, 1 King Street
    Newtown NSW 2042 Australia
    Tel: +61 2 8052 4300
    Fax: +61 2 8052 4301
    info@georgeinstitute.org

    The George Institute country sites:

    • The George Institute country sites:
    • Australia
    • China
    • India
    • UK
    • Affiliated with UNSW Sydney
    • In partnership with Imperial College London
    • In partnership with Manipal Academy of Higher Education

    Social links Global

    • Facebook
    • LinkedIn
    • Twitter
    • YouTube

    Subscribe to our E-newsletter

    Acknowledgement of Country

    The George Institute acknowledges the Gadigal People of the Eora Nation as the Traditional Custodians of the land on which our Australia office and Global Headquarters are built. We pay our respect to Elders past, present and emerging.

    Copyright © 2023 The George Institute

    Footer Links

    • Disclaimer
    • Privacy policy
    • Data sharing policy
    • Whistleblower policy
    • Modern slavery statement
    • Research code policy
    • PHS awards financial COI policy
    • Sitemap
    Please register to download the report
    ×

    Thank you for your interest in the FoodSwitch – State of the Food Supply Report 2022

    You should receive an email with a link to download the report.

    If you don't see it in your inbox, please check you spam folder in case it has been held there.

    Please enter a valid email address
    @Sarika - we need a title here
    ×